1 Min Read
March 13 (Reuters) - Zynerba Pharmaceuticals Inc
* Zynerba Pharmaceuticals announces completion of enrollment for ZYN002 in two Phase 2 clinical trials for epilepsy and osteoarthritis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.